zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2018-15-3-10zdor-57Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEКОРРЕЛЯЦИОННЫЕ ВЗАИМОСВЯЗИ ОПУХОЛЕВОГО МИКРООКРУЖЕНИЯ И ОТНОСИТЕЛЬНЫЙ РИСК НЕБЛАГОПРИЯТНОГО ИСХОДА ЭНДОМЕТРИОИДНОЙ АДЕНОКАРЦИНОМЫ ТЕЛА МАТКИCORRELATIVE INTERRELATIONS OF THE TUMOR MICROENVIRONMENT AND RELATIVE RISK OF UNFAVOURABLE OUTCOME OF ENDOMETRIOID ADENOCARCINOMA OF THE CORPUS UTERIЗиновкинД. А.ZinovkinD. A.noemail@neicon.ruУчреждение образования «Гомельский государственный медицинский университет»Gomel State Medical University201828092018034853Copyright © Зиновкин Д.А., 20182018Зиновкин Д.А.Zinovkin D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/57

Цель: выявить корреляционные взаимосвязи между параметрами опухолевого микроокружения эндометриоидной аденокарциномы и относительного риска ее прогноза. Материалы и методы. Иммуногистохимическое и морфометрическое исследование было проведено на гистологическом материале 60 пациенток. Результаты. Были выявлены корреляционные взаимосвязи между исследуемыми параметрами в группах с благоприятным и неблагоприятным исходами. Определены относительные риски прогрессии эндометриоидной аденокарциномы тела матки. Заключение. Выявленные различия во взаимосвязях между морфологическими и иммуногистохимическими показателями у пациенток с эндометриоидной аденокарциномой тела матки с различной выживаемостью отражают биологические особенности опухолевого роста и прогрессии заболевания

Objective : to identify correlative interrelations among the parameters of the tumor microenvironment of endometrioid adenocarcinoma and relative risk of its prognosis. Material and methods. Immunohistochemic and morphometric studies were performed on the histological material of 60 patients. Results. Correlative interrelations were revealed among the studied parameters in groups with favorable and unfavorable outcomes. Relative risks for progression of endometrioid adenocarcinoma of the corpus uteri were determined. Conclusion. The revealed differences in the interrelations among morphological and immunohistochemical parameters in female patients with endometrioid adenocarcinoma of the corpus uteri of different survival potential reflect biological features of the tumorous growth and the disease progression.

рак эндометрияопухолевое микроокружениепрогнозendometrial cancertumor microenvironmentprognosisReferencesRădulescu D, Cărăuleanu MD. Prognostic factors in endometrial carcinoma. Pathology. 2014;46Rădulescu D, Cărăuleanu MD. Prognostic factors in endometrial carcinoma. Pathology. 2014;46Matias-Guiu X, Davidson B. Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch. 2014 Jul;464(3):315-31.Matias-Guiu X, Davidson B. Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch. 2014 Jul;464(3):315-31.Hahn H-S, Lee I-H, Kim T-J, Lee K-H, Shim J-U, Kim J-W, Lim K-T. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer. Aust N Z J Obstet Gynaecol. 2013;53(3):293-7.Hahn H-S, Lee I-H, Kim T-J, Lee K-H, Shim J-U, Kim J-W, Lim K-T. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer. Aust N Z J Obstet Gynaecol. 2013;53(3):293-7.Hachisuga T, Fukuda K, Nakamura S, Iwasaka T, Sugimori H. Local immune response in endometrial carcinomas. Br J Obstet Gynaecol. 1997;104(1):110-4.Hachisuga T, Fukuda K, Nakamura S, Iwasaka T, Sugimori H. Local immune response in endometrial carcinomas. Br J Obstet Gynaecol. 1997;104(1):110-4.Azueta A, Gatius S, Matias-Guiu X. Endometrioid carcinoma of the endometrium: pathologic and molecular features. Semin Diagn Pathol. 2010;27(4):226-40.Azueta A, Gatius S, Matias-Guiu X. Endometrioid carcinoma of the endometrium: pathologic and molecular features. Semin Diagn Pathol. 2010;27(4):226-40.Zinovkin D, Pranjol MZI. Tumor-Infiltrated Lymphocytes, Macrophages, and Dendritic Cells in Endometrioid Adenocarcinoma of Corpus Uteri as Potential Prognostic Factors. Int J Gynecol Cancer. 2016;26(7):1207-12.Zinovkin D, Pranjol MZI. Tumor-Infiltrated Lymphocytes, Macrophages, and Dendritic Cells in Endometrioid Adenocarcinoma of Corpus Uteri as Potential Prognostic Factors. Int J Gynecol Cancer. 2016;26(7):1207-12.Zinovkin DA, Pranjol MZI, Petrenyov DR, Nadyrov EA, Savchenko OG. The Potential Roles of MELF-Pattern, Microvessel Density, and VEGF Expression in Survival of Patients with Endometrioid Endometrial Carcinoma: A Morphometrical and Immunohistochemical Analysis of 100 Cases. J Pathol Transl Med. 2017;51(5):456-62.Zinovkin DA, Pranjol MZI, Petrenyov DR, Nadyrov EA, Savchenko OG. The Potential Roles of MELF-Pattern, Microvessel Density, and VEGF Expression in Survival of Patients with Endometrioid Endometrial Carcinoma: A Morphometrical and Immunohistochemical Analysis of 100 Cases. J Pathol Transl Med. 2017;51(5):456-62.Geels Y, Pijnenborg J, Erp SVDB-V, Snijders M, Bulten J, Massuger L. Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50%. Gynecol Oncol. 2013;129(2):285-91.Geels Y, Pijnenborg J, Erp SVDB-V, Snijders M, Bulten J, Massuger L. Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50%. Gynecol Oncol. 2013;129(2):285-91.Momeni M, Kolev V, Cardenas-Goicoechea J, Getrajdman J, Fishman D, Chuang L, Kalir T, Rahaman J, Zakashansky K. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens? Am J Obstet Gynecol. 2013;208(1).Momeni M, Kolev V, Cardenas-Goicoechea J, Getrajdman J, Fishman D, Chuang L, Kalir T, Rahaman J, Zakashansky K. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens? Am J Obstet Gynecol. 2013;208(1).Francis S, Boothe D, Werner T, Wolfson A, Gaffney D. The Prognostic Value of Lymphovascular Space Invasion in Locoregional Endometrial Cancer by Adjuvant Treatment and Stage. Brachytherapy. 2017;16(3).Francis S, Boothe D, Werner T, Wolfson A, Gaffney D. The Prognostic Value of Lymphovascular Space Invasion in Locoregional Endometrial Cancer by Adjuvant Treatment and Stage. Brachytherapy. 2017;16(3).Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: Towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol. 2014;97(3):585-9.Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: Towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol. 2014;97(3):585-9.Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27(10):521-30.Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-tumor immunity. Int Immunol. 2015;27(10):521-30.Gulubova M, Ivanova K, Ananiev J, Gerenova J, Zdraveski A, Stoyanov H, Vlaykova T. VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer. Biotechnol Biotechnol Equip. 2014 Apr;28(3):508-17.Gulubova M, Ivanova K, Ananiev J, Gerenova J, Zdraveski A, Stoyanov H, Vlaykova T. VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer. Biotechnol Biotechnol Equip. 2014 Apr;28(3):508-17.Malyguine A, Dunham K, Sayers TJ, Shurin MR. Evaluation of the Tumor Immunoenvironment in Clinical Trials. The Tumor Immunoenvironment. 2013:695-706.Malyguine A, Dunham K, Sayers TJ, Shurin MR. Evaluation of the Tumor Immunoenvironment in Clinical Trials. The Tumor Immunoenvironment. 2013:695-706.Schmid BC, Oehler MK. Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers. Curr Treat Options Oncol. 2015;16(1).Schmid BC, Oehler MK. Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers. Curr Treat Options Oncol. 2015;16(1).

The authors declare that there are no conflicts of interest present.